Security Snapshot

Tonix Pharmaceuticals Holding Corp - Common Stock (TNXP) Institutional Ownership

CUSIP: 890260854

13F Institutional Holders and Ownership History from Q2 2023 to Q3 2024

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / Common Stock
Symbol
TNXP on Nasdaq
Shares outstanding
186,616,143
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • TNXP - Tonix Pharmaceuticals Holding Corp - Common Stock is tracked under CUSIP 890260854.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 0 between Q2 2024 and Q3 2024.
  • Reported value moved from $19,636 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 890260854?
CUSIP 890260854 identifies TNXP - Tonix Pharmaceuticals Holding Corp - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of Tonix Pharmaceuticals Holding Corp - Common Stock (TNXP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SABBY MANAGEMENT, LLC 0.7% $143,694 1,306,313 SABBY MANAGEMENT, LLC 31 Dec 2024

Institutional Holders of Tonix Pharmaceuticals Holding Corp - Common Stock (TNXP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2024 Q3 0 $0 -$19,636 0
2024 Q2 28,155 $19,636 -$2,066,231 $0.85 2
2024 Q1 13,393 $2,493 -$220,889 $1.00 5
2023 Q4 14,436,164 $5,809,652 +$3,945,317 $0.40 34
2023 Q3 3,694,288 $2,013,385 +$1,372,274 $0.54 29
2023 Q2 1,023,358 $1,616,253 +$1,616,250 $1.58 30